u/marit_sandvik

Not convinced by four data points. That is not a lane yet, it is an anecdote with a route attached.

This.

Saving this one. It is the clearest statement of the stall problem I have read here.

Push back: daily dosing is not automatically better adherence. It is a different failure mode, not a solved problem.

ask for the batch record before you ask for a discount

hold the dose that works, the ladder is not a leaderboard

Scotland, Wales and Northern Ireland have their own arrangements. An answer that begins with "in England" should say so, and most of the confusion here comes from answers that do not.

Correction to my own post above — I said 2.5mg and I have been on 15mg since the spring. Same argument, wrong number.

Push back: comparing a July transit with a February one on the same lane is not a comparison.

Six orders across two years from WXT. Same packaging, same paperwork, same lead time. The most boring supplier relationship I have and I mean that as praise.

two identical orders a week apart is the cheapest experiment available

Where a supplier holds regional stock, ask which lines are actually held there rather than drop-shipped. It changes the lead time and it changes the customs question.

the last mile is where most of the variance lives

Which lane, and what was the quoted lead time at checkout?

Lead time and minimum quantity are the two facts people forget to ask for and then argue about later. Both are answerable in one email before you commit.

Milligram-for-milligram comparison with an injectable peptide is not meaningful and I should not have made it.

What analytical method was used — this is not the usual peptide assay question?

Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.

SURMOUNT-1 landed around 21% at 72 weeks on the top arm

Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.

Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.

Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.

a directory entry is a record, not a recommendation

a lot of people plateau nicely at 10mg and never need 15

Daily dosing gives a very different exposure profile from a weekly injectable: peaks and troughs within each day rather than a smoothed weekly curve.

research-use-only means not approved for human use, and here that covers everything

Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.

tier 3 waiting lists are measured in years, not months

What did the referral letter actually say?

Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.

Cosigning that the papers are more modest than the summaries of them. That is true across this whole site and especially here.

a claim with no batch number is a marketing document

Research-use-only material is not approved for human use. Anything in this thread about how a research vial "should" titrate is a discussion about chemistry, not a plan.

the interesting column is spread, not maximum

Which lane, and what was the quoted lead time at checkout?

Which week did the appetite change actually land for you?

zepbound and mounjaro are the same compound with different labels